Fierce Pharma
JUNE 20, 2024
For the first time, an HIV PrEP drug candidate has shown zero infections in a phase 3 trial. | For the first time, an HIV PrEP drug candidate has shown zero infections in a phase 3 trial. For Gilead, it serves as one of two pieces for a potential FDA filing. For GSK, it means a major competitor could be looming around the corner.
David Bagga
JUNE 20, 2024
Medical Device Sales Academy 6 Steps for Success in the Medical Sales Field The medical representative works to deliver the company’s ideas and messages to the healthcare reps in the most efficient, understandable, and intelligible way. The best way to help improve their service is to provide all necessary information, equipment, and opportunities to enhance […] The post 6 Steps for Success in the Medical Sales Field appeared first on.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JUNE 20, 2024
Eli Lilly is stepping up its effort to combat the improper sale of compounded versions of its popular diabetes and weight loss drugs. | Eli Lilly is stepping up its effort to combat the improper sale of compounded versions of its popular diabetes and weight loss drugs. The Indianapolis-based drugmaker is suing six wellness centers, medical spas and others that it claims are using "deceptive" advertising.
MedCity News
JUNE 20, 2024
Under the Affordable Care Act, most private health insurance plans are required to cover birth control methods approved by the FDA without out-of-pocket costs. But not all plans are doing this, Bernie Sanders declared in a letter. The post Bernie Sanders Urges GAO To Investigate Payers Over Birth Control Coverage appeared first on MedCity News.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Fierce Pharma
JUNE 20, 2024
There’s no slowing the momentum of Sarepta’s groundbreaking Duchenne muscular dystrophy (DMD) gene therapy Elevidys—not even the failure of a confirmatory trial. | The FDA has expanded the label for Sarepta's Elevidys to all Duchenne muscular dystrophy patients ages 4 and older. It’s a major boost for the first gene therapy to treat the inherited disorder, which received an accelerated approval a year ago—nearly to the date—but only for ambulatory boys ages 4 to 5.
MedCity News
JUNE 20, 2024
A proactive cybersecurity stance can maintain the integrity of healthcare, ensuring that care remains both continuous and secure. The post Hacking the Hippocratic Oath: Four Ways to Shield Patients from Ransomware Attacks appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
European Pharmaceutical Review
JUNE 20, 2024
Researchers have developed a novel, gloveless intervention method with remote robotic interventions for high-speed pharmaceutical isolator filling lines. While these high-speed lines are currently fully automated, Dekker et al. noted that operator interventions are still done manually. For example, a common intervention is the removal of erroneous plungers or stoppers.
Fierce Pharma
JUNE 20, 2024
After plugging nearly 50 million euros into its Italy operations in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country.
MedCity News
JUNE 20, 2024
Virtual first models can address a brutal trifecta of challenges – access, cost, and quality. The post Three Healthcare Challenges Overcome by Virtual Specialty Care — And Why Employers Should Take Note appeared first on MedCity News.
Fierce Pharma
JUNE 20, 2024
A series of increasing buyout offers has failed to convince Vanda's board of directors that the company should sell itself. | Vanda is turning away buyout offers from Future Pak and Cycle Pharma. In a statement, Vanda said its revenue base, cash position and efficient operations position the company "for significant long-term growth and value creation far in excess of the" other firms' offers.
European Pharmaceutical Review
JUNE 20, 2024
Small molecule drugs have been a critical part of the pharmaceutical toolbox for over a century. Most can be taken orally and pass through cell membranes to reach intercellular targets, however, recent advancements in areas such as AI and machine learning have seen the potential for new small molecule-based therapeutics grow exponentially. One example of this is Takeda’s small molecule drug, fruquintinib, which has been shown to be an effective treatment for heavily pretreated metastatic colorec
Fierce Pharma
JUNE 20, 2024
On a revised dealmaking spree this year, Korea’s Samsung Biologics is re-tooling its long-running drug manufacturing pact with Baxter Healthcare. | The revised deal, first established back in July of 2017, will now see Baxter pay Samsung upwards of $223 million for its manufacturing services through end of 2034. Previously, Baxter was on the hook to pay just $15 million for Samsung’s production assistance.
PharmaVoice
JUNE 20, 2024
One expert described trial results presented at EULAR last week as “unprecedented.” But reports of relapses in some patients drew questions about the therapies’ ultimate potential.
Fierce Pharma
JUNE 20, 2024
Everybody sweats, but for the 10 million people in the U.S. living with primary axillary hyperhidrosis, sweating can take on a whole new meaning. | The med is the first new chemical entity to win FDA approval specifically to treat primary axillary hyperhidrosis, or excessive underarm sweating. It's also Botanix's first approved product.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
MedCity News
JUNE 20, 2024
Value-based care results in a lot of added administrative tasks for physicians — so much so that one health system leader believes value-based care will never reach true scale unless providers figure out how to ease that burden. The adoption of new technology, coupled with workflow training from fellow physicians, can help address this issue, population health experts say.
Fierce Pharma
JUNE 20, 2024
AbbVie’s fast-growing Humira successor Skyrizi is already on a roll with skyrocketing sales. | Since its original nod in 2019, AbbVie's IL-23 inhibitor has added several new uses over the years. Now, its fourth approved disease area is ulcerative colitis.
pharmaphorum
JUNE 20, 2024
AbbVie’s Skyrizi is approved by the FDA for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease.
Fierce Pharma
JUNE 20, 2024
BioNTech and MediLink's HER3 ADC has been put on a partial clinical hold by the FDA. Takeda has identified a potential challenger to Novartis' Scemblix. Senior officials from China and U.S. | BioNTech and MediLink's HER3 ADC has been put on a partial clinical hold by the FDA. Takeda has identified a potential challenger to Novartis' Scemblix.
pharmaphorum
JUNE 20, 2024
Sarepta gets best-case approval from the FDA for an expansion to the label for its Duchenne muscular dystrophy gene therapy Elevidys.
PharmaVoice
JUNE 20, 2024
Many clinical trials aren’t meeting enrollment inclusion checkpoints — and some aren’t even setting targets, according to a recent OIG report.
pharmaphorum
JUNE 20, 2024
International Society for Infectious Diseases (ISID) publishes six priorities focusing on challenges faced by low- and middle-income countries (LMICs).
MedCity News
JUNE 20, 2024
FDA draft guidance eliminates the requirement that biosimilars produce clinical data to show they are interchangeable with their reference drugs. Some lawmakers have said these so-called switching studies add time and expense to the development of biosimilars, delaying them from reaching patients. The post FDA Mulls Policy Switch on Switching Study Requirement for Biosimilars appeared first on MedCity News.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
JUNE 20, 2024
After rejection of its multiple myeloma therapy Sarclisa by NICE, Sanofi claims the drug would not have been deemed cost-effective 'even at zero price'
PharmaTimes
JUNE 20, 2024
The progressive neurodegenerative condition affects more than ten million people worldwide
pharmaphorum
JUNE 20, 2024
Vanda Pharma is unimpressed with takeover offers from Cycle Pharma and Future Pak, saying they both substantially undervalue the company
PharmaTimes
JUNE 20, 2024
The lifelong inflammatory bowel disease affects around one in every 350 people in the UK
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
JUNE 20, 2024
Common alpha-blocker prostate drugs linked to lower risk of dementia with Lewy bodies in large-scale observational study.
Pharmaceutical Commerce
JUNE 20, 2024
The latest news for pharma industry insiders.
Clarify Health
JUNE 20, 2024
Recently, Clarify Health ‘s CEO Terry Boch moderated a panel during an event at AHIP 2024 , focused on engagement between health plans and providers. Formerly known as America’s Health Insurance Plans, AHIP is a professional advocacy association for providers of health care coverage, services, and solutions; its annual flagship conference has been a destination for industry leaders for decades.
PharmaTech
JUNE 20, 2024
Standardized manufacturing through a Recipe-Driven Execution environment and digital twins minimizes effort duplication while simplifying operations, harmonizing production processes, and accelerating speed to patient.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
360 
Let's personalize your content